IMAP 2018

Conference Co-Chairs

Steven Cobb

Durham University

Julia Dorin

University of Edinburgh

Organising Committee

Kai Hilpert, St. Georges University of London, UK
Ralf Hoffmann, Leipzig University, Germany
Karl Lohner, University of Graz, Austria
Edwin Veldhuizen, Utrecht University, Netherlands

IMAP 2018 was held under the auspices of the Protein & Peptide Science Group of the Royal Society of Chemistry.

Poster Prizes

The Protein & Peptide Scicence group of the RSC sponsors the Poster Prizes at IMAP 2018.

Continuing a Successful Series

IMAP 2018 built on the success of the previous meetings held in Copenhagen, Denmark (IMAP 2017), Leipzig, Germany (IMAP 2008, 2012 and 2016), London, UK (IMAP 2013 and 2015) and Graz, Austria (IMAP 2014).

Antimicrobial Peptides (AMPs) and Host Defence Peptides (HDPs)

The 8th International Meeting on Antimicrobial Peptides (IMAP 2018) took place over 2 1/2 days in Edinburgh, UK in September 2018.

IMAP 2018 covered both the antimicrobial activity of peptides as well as their role in regulation and modulation of the immune system.

This was the biggest IMAP so far, with over 130 delegates and speakers.

Scientific Programme

Design, synthesis and mode of action of AMPs / HDPs, including:
- Immunomodulatory aspects
- Biophysical aspects
Human and veterinary therapeutic applications of AMPs / HDPs
Role of AMPs / HDPs in fertility and reproduction
AMPs / HDPs in immune modulation and Alzheimer’s disease
Peptide biomaterials, peptide-polymer hybrids
Susceptibility testing of AMPs

The Programme is now available on the Programme & Abstracts page.

Confirmed Speakers

Annelise Barron, Stanford School of Medicine, USA
Margaret Brimble, University of Auckland, New Zealand
Matthew Cooper, University of Queensland, Australia
Carl N. Kraus, Arrevus, USA
Kieran Meade, Teagasc, Ireland
Victor Nizet, UCSD, USA
Jennifer Payne, Monash University, Australia
Joel Schneider, NIH CCR, USA
Marc Vendrell, University of Edinburgh, UK
Bill Wimley, Tulane University, USA

Conference Sponsor

The organisers are grateful to NovaBiotics Ltd. for their continuing generous financial support of the meeting.

NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.

For more information, please visit the NovaBiotics website.